Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ALG5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ALG5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ALG5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ALG5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ALG5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00181969 | Esophagus | ESCC | peptidyl-asparagine modification | 22/8552 | 24/18723 | 2.82e-06 | 3.21e-05 | 22 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00182799 | Esophagus | ESCC | protein N-linked glycosylation via asparagine | 21/8552 | 23/18723 | 5.69e-06 | 5.90e-05 | 21 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00182795 | Liver | Cirrhotic | protein N-linked glycosylation via asparagine | 16/4634 | 23/18723 | 7.54e-06 | 1.15e-04 | 16 |
GO:00181965 | Liver | Cirrhotic | peptidyl-asparagine modification | 16/4634 | 24/18723 | 1.74e-05 | 2.37e-04 | 16 |
GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
GO:000648711 | Liver | HCC | protein N-linked glycosylation | 48/7958 | 65/18723 | 2.85e-07 | 5.00e-06 | 48 |
GO:001819611 | Liver | HCC | peptidyl-asparagine modification | 21/7958 | 24/18723 | 6.62e-06 | 7.97e-05 | 21 |
GO:001827911 | Liver | HCC | protein N-linked glycosylation via asparagine | 20/7958 | 23/18723 | 1.37e-05 | 1.51e-04 | 20 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00181968 | Oral cavity | OSCC | peptidyl-asparagine modification | 20/7305 | 24/18723 | 1.10e-05 | 1.14e-04 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG5 | SNV | Missense_Mutation | | c.409C>A | p.Leu137Met | p.L137M | Q9Y673 | protein_coding | deleterious(0.02) | possibly_damaging(0.718) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ALG5 | SNV | Missense_Mutation | rs542695178 | c.121N>A | p.Glu41Lys | p.E41K | Q9Y673 | protein_coding | tolerated(0.52) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ALG5 | SNV | Missense_Mutation | novel | c.185N>T | p.Ser62Leu | p.S62L | Q9Y673 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
ALG5 | SNV | Missense_Mutation | | c.650A>G | p.Tyr217Cys | p.Y217C | Q9Y673 | protein_coding | deleterious(0.01) | probably_damaging(0.926) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG5 | SNV | Missense_Mutation | | c.138N>A | p.Phe46Leu | p.F46L | Q9Y673 | protein_coding | deleterious(0.03) | possibly_damaging(0.824) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
ALG5 | SNV | Missense_Mutation | | c.89N>T | p.Thr30Ile | p.T30I | Q9Y673 | protein_coding | tolerated(0.08) | benign(0.027) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ALG5 | deletion | Frame_Shift_Del | novel | c.719delT | p.Leu240TyrfsTer23 | p.L240Yfs*23 | Q9Y673 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ALG5 | deletion | Frame_Shift_Del | novel | c.132delN | p.Lys44AsnfsTer4 | p.K44Nfs*4 | Q9Y673 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ALG5 | SNV | Missense_Mutation | novel | c.947G>A | p.Arg316Lys | p.R316K | Q9Y673 | protein_coding | tolerated(1) | benign(0) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALG5 | SNV | Missense_Mutation | | c.635G>A | p.Arg212His | p.R212H | Q9Y673 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |